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XBackground: Preoperative extracorporeal membrane oxygenation (ECMO) is a risk factor for poor outcome and
currently considered a contraindication to lung transplantation. The lung allocation score systemwas introduced
inMay 2005 and prioritizes lung allocation to those with the greatest respiratory impairment. The purpose of this
study is to determinewhether ECMOas a bridge to lung transplantation is an acceptable option to support those in
respiratory failure until donor lungs become available in the lung allocation score era.
Method:A retrospective review of 715 consecutive lung transplants performed betweenMay 2005 and Septem-
ber 2011 was conducted using a prospectively collected institutional registry database. Twenty-four lung trans-
plants (3.4%) were performed in the 31 patients with attempted pretransplant ECMO; 7 patients who received
ECMO patients did not survive or were deemed unfit for transplantation. These patients were compared with
a control group of 691 patients who did not receive pretransplant ECMO.
Results: The duration of pretransplant ECMOwas 171 242 hours (median, 91 hours). Venovenous ECMOwas
used for respiratory failure in 15 patients, whereas venoarterial ECMOwas used for circulatory collapse due to pul-
monaryhypertension in 9patients. Patients in the retransplantECMOgroupwereyounger (46 15years vs 57 14
years,P<.01) comparedwith the control group, with no difference in recipient gender (male/female: 10/14 vs 380/
311), donor age (33 14 years vs 36 15 years), or donor gender (male/female: 10/14 vs 352/339). Emphysema
was less common (1, 4% vs 260, 38%, P<.01), and cystic fibrosis (5, 21% vs 72, 10%, P¼ .09), redo lung trans-
plant (3, 13%vs28, 4%,P¼ .08), and bronchiectasis (2, 8%vs6, 1%,P¼ .03)weremore common in thepretrans-
plant ECMO group. Patients in the pretransplant ECMO group had a significantly higher lung allocation score
(87  9 vs 44  15, P<.01). All patients in the pretransplant ECMO group underwent double lung transplants
on pump (cardiopulmonary bypass/ECMO), and single lung transplants were performed in 171 patients (25%)
and pump was used in 243 patients (35%) in the control group. The cardiopulmonary bypass time was longer in
the pretransplant ECMO group (277 69 minutes vs 225 89 minutes, P¼ .02), with no difference in ischemic
time (343 93minutes vs 330 98minutes,P¼ .54). Cadaveric lobar lung transplantswere performed because of
the urgency to overcome size mismatch with an oversized donor more frequently in 25% (n¼ 6, no mortality with
the longest follow-up at 6 years) of patients in the pretransplant ECMOgroup versus 0.3% (n¼ 2) of patients in the
control group (P<.01). Post-transplant ECMOwas used for primary graft dysfunction in 13 patients (54%) in the
pretransplant ECMO group and 41 patients (6%) in the control group (P<.01). The median hospital stay was 46
days in the pretransplant ECMO group versus 27 days in the control group (P¼ .16). The actuarial survivals after
lung transplants at 1, 3, 6, 12, and 24 months were 96%, 88%, 83%, 74%, and 74%, respectively, in the pretrans-
plant ECMO group, and 97%, 94%, 90%, 83%, and 74%, respectively, in the control group (P ¼ .787).
Conclusions: Although the incidence of primary graft dysfunction requiring post-transplant ECMO is higher
and the hospital stay is longer in patients receiving pretransplant ECMO, the graft survival is good (2-year sur-
vival, 74%). ECMO is efficacious as a bridge to lung transplantation with good post-lung transplant outcomes.
(J Thorac Cardiovasc Surg 2013;145:1065-71)Extracorporeal membrane oxygenation (ECMO) has been
used in clinical medicine for 40 years, but it remains a con-
troversial therapy.1 ECMO has been used as a life-support
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Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
LAS ¼ lung allocation score
UNOS ¼ United Network for Organ Sharing
VA ¼ venoarterial
VV ¼ venovenous
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Xto be significant risk factors for mortality in lung transplan-
tation.2 Because patients receiving ECMO are hospitalized
and almost always on mechanical ventilation, it has been
controversial whether patients on ECMO should receive
lung transplantation, and in reality, these patients have
been frequently denied for listing or removed from the wait-
list, resulting in pretransplant mortality. Mason and col-
leagues3 analyzed United Network for Organ Sharing
(UNOS) data from 1987 to 2008 and found that only 51
patients (0.3%) in the United States were on ECMO preop-
eratively. The 1- and 2-year survivals were 50% and 45%,
respectively, for patients with pretransplant ECMO com-
pared with 79% and 70%, respectively, for unsupported
patients. Therefore, ECMO has been considered a contrain-
dication for lung transplantation in many centers because of
the poor outcomes.
Before the introduction of the current lung allocation
score (LAS) system in the United States in May 2005,4
lung allocation was primarily based on waiting time. The
waiting time–based lung allocation favors patients well
enough to wait the longest and does not favor critically ill
patients who cannot wait for a prolonged period of time.5
Therefore, patients on ECMO might have to wait for
a long time, and the outcomes of lung transplantation would
be suboptimal because complications such as muscular de-
conditioning, infection, thromboembolism, bleeding, and
poor nutrition could occur while waiting on ECMO. How-
ever, with the LAS system, critically ill patients who are
in imminent danger of death and therefore in direst need
of lung transplantation receive a high score and have prior-
ity of lung allocation.4,5 Patients on ECMO have a high
LAS,3 possibly resulting in finding suitable donor lungs in
a timely fashion, and therefore potentially leading to better
outcomes.
We have recently reported our experience of pretrans-
plant ECMO.6 However, the study included both lung and
heart-lung transplant recipients and patients who were
under various protocols from 1991 to 2010. In addition to
the change in the lung allocation in 2005, we have made
several important changes in our protocols, including pres-
ervation solution of the donor lungs, intraoperative pulmo-
nary protection, postoperative ventilator management, and
immunosuppression from 1991 to 2003.7,8 Therefore, the
purpose of this study was to review the efficacy of ECMO
as a bridge to lung transplantation, not including1066 The Journal of Thoracic and Cardiovascular Surheart-lung transplantation, following the instrumentation
of the current LAS system in 2005 in our current, standard-
ized protocols at a single institution.PATIENTS AND METHODS
Study Protocol
The University of Pittsburgh Medical Center lung transplant evaluation
and recipient research registry is approved by the University of Pittsburgh
Institutional Review Board for the use of patient management, quality
assurance reports, and clinical research. Data were prospectively collected
into the Transplant PatientManagement System.We performed a retrospec-
tive analysis of consecutive patients, from May 2005 to September 2011,
who underwent lung transplant (primary and retransplantation). Data
were obtained from the University of Pittsburgh Medical Center transplant
database and patient charts. This study was approved by the Total Quality
Council at the University of Pittsburgh Medical Center. The informed
consent requirement was waived.
Patient Selection
ECMO was selectively used to support patients with advanced cardio-
pulmonary failure unresponsive to maximal medical therapy, such as
mechanical ventilation support with 100% inspired oxygen fraction, posi-
tive end-expiratory pressure, and use of inhaled nitric oxide and inotropes.
ECMO was considered for patients who presented a rapid deterioration of
a chronic lung diseasewhile on thewaiting list or during the lung transplant
evaluation process. Three patients on ECMO support for primary graft fail-
ure after the primary lung transplant with the absence of lung recovery were
selectively considered for redo lung transplantation. We considered
retransplantation in the context of primary graft dysfunction when other
organ functions were intact. We excluded patients who did not meet stan-
dard criteria for lung transplant candidacy. Therefore, patients with other
established organ dysfunctions, including renal failure, liver failure, major
stroke, and sepsis, were denied. Patients who underwent lung transplanta-
tion without the use of pretransplant ECMO during the period analyzed
served as a control group.
Lung Transplant Protocols
During the study period 2005 to 2011, standardized protocols were
applied, which have been described.7,8 In summary, for donor lung
procurement, a bolus injection of prostaglandin E1 500 mg was
administered into the main pulmonary artery immediately before
crossclamp. An additional 500 mg of prostaglandin E1 and 50 mg of
nitroglycerin were added in the first bag of Perfadex (Vitrolife AB,
Gothenburg, Germany). We administered 70 mL/kg of Perfadex
antegradely through the main pulmonary artery in the operative field and
1 liter of Perfadex for each lung retrogradely through the pulmonary
veins at the back table. During the recipient surgery, 800 mL of cold
blood with glutamate, aspartate, lidocaine, adenosine, nitroglycerin,
verapamil, deferoxamine, ascorbic acid, dextrose, and insulin, as
described previously,7 were given antegradely through the pulmonary
artery after the bronchial anastomosis, and 800 mL of terminal warm blood
with the same additives were given antegradely through the pulmonary
artery before reperfusion to protect the allograft. Protective ventilatory
management with low tidal volume (6 mL/kg of the donor body weight)
and high positive end-expiratory pressurewas used postoperatively. For im-
munosuppression, our standard immunosuppressive induction became
alemtuzumab (Campath 1-H; Genzyme Corporation, Cambridge, Mass)
in 2003, which was given intraoperatively. For maintenance immunosup-
pression, a triple drug regimen including tacrolimus, mycophenolate mofe-
til in half dose (750 mg twice daily), and minimized steroid (5 mg once
daily) were used. For infection prophylaxis, valganciclovir was used for
cytomegalovirus and voriconazole was used for fungus and yeast.gery c April 2013
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Methodology
Venovenous (VV) ECMOwas the preferred method for respiratory fail-
ure in lung transplant candidates. Venoarterial (VA) ECMOwas used when
patients had cardiac failure in addition to respiratory failure. A Medtronic
Carmeda (Medtronic Inc, Minneapolis, Minn) heparin-bonded Affinity
oxygenator or QuadroxD oxygenator (Maquet Cardiopulmonary, Rastatt,
Germany) was used in this study. Heparin (5000 units) was administered
at the time of ECMO implantation and then titrated to maintain an activated
clotting time of 140 to 160 seconds with VVECMO and 180 to 200 seconds
with VA ECMO.
Data Analysis
Statistical analysis was performed using the Statistical Package for the
Social Sciences version 14.0 (SPSS Inc, Chicago, Ill). Continuous variables
are shown as mean standard deviation or median. The unpaired, 2-tailed
t test was used to compare independent continuous variables between the 2
groups. The Fisher exact test was used to determine whether there are non-
random associations between 2 categoric variables. Kaplan–Meier analysis
was used to calculate actuarial survival, and the log-rank test was used to
test the null hypothesis that there is no difference in Kaplan–Meier survival
curve between the groups.TABLE 1. Patient characteristics
Pretransplant
ECMO Control P value
No. 24 (3.4%) 691 (96.6%) —
Recipient age (y) 46  15 57  14 <.01
Recipient gender 10 men (42%)/14
women (58%)
380 men (55%)/311
women (45%)
.216
Donor age (y) 33  14 36  15 .202
Donor gender 10 men (42%)/14
women (58%)
352 men (51%)/339
women (49%)
.412
LAS 87  9 44  15 <.01
Transplant type <.01
Single lung 0 (0%) 171 (25%)
Double lung 24 (100%) 520 (75%)
Cadaveric lobar
transplant
6 (25%) 2 (0.3%) <.01
CPB/ECMO use 24 (100%) 243 (35%) <.01
CPB time (min) 277  69 225  89 .02
Ischemic time per
lung (min)
343  93 330  98 .54
Use of post-transplant
ECMO
13 (54%) 41 (6%) <.01
Median hospital
stay (d)
46 27 .16
ECMO, Extracorporeal membrane oxygenation; LAS, lung allocation score;
CPB, cardiopulmonary bypass.
T
XRESULTS
Cohort Characteristics
The total cohort included 715 consecutive lung trans-
plants. Of these, 24 (3.4%) were performed for patients
who were brought to the operating room already on pre-
transplant ECMO (pretransplant ECMO group), whereas
691 patients (96.6%) did not receive ECMO support before
lung transplant (control group). An additional 7 patients
were placed on ECMO with the intent to perform transplan-
tation, but for various reasons they did not undergo trans-
plantation and died. Intraoperative insertion of ECMO
was not considered as pretransplant ECMO. Of 24 patients,
15 required VV ECMO alone and 9 required VA ECMO. In
VV ECMO (n ¼ 15), the femoral vein and internal jugular
vein were the most common cannulation sites (n¼ 10), fol-
lowed by dual-lumen cannula through the right internal
jugular vein (Avalon Elite [Avalon Laboratories, LLC, Ran-
cho Dominguez, Calif] n ¼ 3) and femoral vein–femoral
vein (n ¼ 2). In VA ECMO (n ¼ 9), femoral vein–femoral
artery (n ¼ 4), right atrium–ascending aorta (n ¼ 4), and
internal jugular vein–femoral artery (n ¼ 1) were the most
common cannulation sites. The duration of pretransplant
ECMO support in the pretransplant ECMO group was
171  242 hours (range, 2-1104 hours). Superior vena
cava obstruction due to 27F dual-lumen cannula in the right
internal jugular vein occurred in 1 patient, and the ECMO
was converted to central VA ECMO with the right atrium
to ascending aorta via the right thoracotomy. Three other
patients who received right-atrium-ascending aorta central
VA ECMO underwent their primary lung transplants and
the ECMO was used as a bridge to retransplantation. Pa-
tients in the pretransplant ECMO group were significantly
younger than patients in the control group (P<.01). ThereThe Journal of Thoracic and Carwere no differences in recipient gender, donor age, and do-
nor gender between the groups. The LAS for the pretrans-
plant ECMO group was significantly higher compared
with the control group, with scores of 87  9 and
44  15, respectively (P < .01) (Table 1). Emphysema
was less common (4%) in the pretransplant ECMO group
compared with 38% in the control group (P<.01). Cystic
fibrosis (P ¼ .09), bronchiectasis (P ¼ .03), and redo lung
transplants (P ¼ .08) were more common in the pretrans-
plant ECMO group (Table 2). Seven patients started on
ECMO as a potential bridge to transplant did not undergo
transplantation and died while on ECMO support. There-
fore, the bridge to lung transplant success rate was 77%.
ECMO was not considered for patients who had multiple
organ failure, resulting in deaths on the waiting list.Operative Characteristics
All patients in the pretransplant ECMO group underwent
double lung transplants (24/24; 100%), whereas 75%
(520/691) of the patients in the control group underwent
double lung transplants (P<.01). Pump (cardiopulmonary
bypass or ECMO) was used in all patients in the pretrans-
plant ECMO group, whereas only 35% (243/691) of the
patients required pump in the control group to perform
lung transplants (P< .01). Cardiopulmonary bypass time
was longer for the pretransplant ECMO group (277  69
minutes) than for the control group (225  89 minutes)
(P¼ .02). The ischemic timewas similar between the groupsdiovascular Surgery c Volume 145, Number 4 1067
TABLE 2. Diagnosis
Pretransplant
ECMO (N ¼ 24)
Control
N ¼ 691
P
value
COPD 1 (4%) 260 (38%) <.01
IPF/fibrosis 8 (33%) 219 (32%) .827
Cystic fibrosis 5 (21%) 72 (10%) .091
Scleroderma/MCTD/Wegener’s 3 (13%) 48 (7%) .241
Bronchiectasis 2 (8%) 6 (1%) .027
Sarcoidosis 1 (4%) 18 (3%) .482
Primary pulmonary hypertension 1 (4%) 11 (2%) .338
Redo lung transplantation 3 (13%) 28 (4%) .081
Others 0 (0%) 29 (4%) .618
ECMO, Extracorporeal membrane oxygenation; COPD, chronic obstructive pulmo-
nary disease; IPF, idiopathic pulmonary fibrosis; MCTD, mixed connective tissue
disease.
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X(343  93 minutes in the pretransplant ECMO group vs
330  98 minutes in the control group) (P ¼ .54) (Table 1).Cadaveric Lobar Transplantation
Cadaveric lobar lung transplantation was selectively per-
formed to overcome size discrepancy. To minimize the
waiting time, given the critical condition of patients on pre-
transplant ECMO, 25% of patients in the pretransplant
ECMO group received cadaveric lobar transplantation ver-
sus 0.3% of patients in the control group (P< .01). The
characteristics and intraoperative and postoperative data
of the 6 patients are shown in Table 3.Postoperative Characteristics
ECMO support was used postoperatively for primary graft
dysfunction in 54% of patients in the pretransplant ECMO
group and 6% of patients in the control group (P< .01).TABLE 3. Cadaveric lobar transplants in double lung transplantation for p
Patient 1 2
Recipient age (y) 36 54
Recipient gender Male Female
Recipient height (cm) 180 152
Donor age (y) 52 21
Donor gender Female Male
Donor height (cm) 170 180
Diagnosis Fibrosis Sarcoidosis
LAS 89 93
Lobar transplant LLL LLL
Pretransplant ECMO
Type VA VA
Duration (h) 2 13
CPB time (min) 243 181
Ischemic time left/right (min) 277/377 406/311
Post-transplant ECMO No No
Hospital stay (d) 59 24
Graft status (d) Alive (2476) Alive (365)
LAS, Lung allocation score; ECMO, extracorporeal membrane oxygenation; CPB, cardiopu
lower lobe; RLL, right lower lobe; RUL, right upper lobe; RML, right middle lobe; VA, ve
1068 The Journal of Thoracic and Cardiovascular SurThe median hospital stay for the pretransplant ECMO group
was longer (46 days) than for the control group (27 days)
(P ¼ .155). Patients in the pretransplant ECMO group who
also required post-transplant ECMO for severe primary graft
dysfunction received a significantly greater amount of blood
transfusion (31.8  5.7 units) compared with patients in the
pretransplant ECMO group who did not require post-
transplant ECMO (17.3  2.8 units, P ¼ .04).
Survival
In the pretransplant ECMO group, 1 patient (4%) died
within 30 days and 3 patients (13%) died within 90 days.
In the control group, 24 patients (3%) died within 30
days and 43 patients (6%) died within 90 days. Twenty
patients (83%) in the pretransplant ECMO group were dis-
charged from the hospital, and 649 patients (91%) in the
control group were discharged from the hospital. The actu-
arial survivals after lung transplantation at 1, 3, 6, 12, and 24
months were 96%, 88%, 83%, 74%, and 74%, respec-
tively, in the pretransplant ECMO group, and 97%, 94%,
90%, 83%, and 74%, respectively, in the control group
(P ¼ .787, Figure 1). There was no statistical difference
(P ¼ .544) in the overall actuarial survival after lung trans-
plant for patients with pretransplant VV ECMO versus pa-
tients with VA ECMO, with survivals of 100%, 93%, 87%,
77%, and 77% at 1, 3, 6, 12, and 24months, respectively, in
the pretransplant VV ECMO group and 89%, 78%, 78%,
65%, and 65% at 1, 3, 6, 12, and 24 months, respectively,
in the pretransplant VA ECMO group.
DISCUSSION
This study examines a large single-center experience in
the use of pretransplant ECMO support as a bridge toatients on pretransplant extracorporealmembrane oxygenation (N¼ 6)
3 4 5 6
54 28 29 56
Female Female Male Male
163 145 170 183
42 30 38 18
Female Male Female Male
173 183 170 173
MCTD CF CF Wegener’s
91 89 82 90
RLL RUL þ RML RUL RUL þ RLL
VV VA VV VV
290 352 124 96
205 319 287 450
228/323 354/260 449/449 530/367
No No No yes
48 51 42 47
Alive (333) Alive (281) Alive (228) Alive (220)
lmonary bypass;MCTD, mixed connective tissue disease; CF, cystic fibrosis; LLL, left
noarterial; VV, venovenous.
gery c April 2013
FIGURE 1. Kaplan–Meier graft survival after lung transplantation.
Tx, Transplantation; ECMO, extracorporeal membrane oxygenation.
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Xlung transplant over a 6-year period (2005-2011) after the
adoption of the LAS system in the United States. In our ex-
perience, 3.4% of the lung transplant recipients were on
ECMO preoperatively, which is significantly higher than
0.3% in the UNOS data from 1987 to 2008.3 The recipient
age of patients with pretransplant ECMO was 46  15
years, which was also significantly higher than the recipient
age of 39  22 years in the UNOS data.3 Our oldest recip-
ient with pretransplant ECMO was aged 69 years. Of the 24
patients on pretransplant ECMO, 3 (13%) had redo lung
transplants and 2 (8%) had scleroderma. These are known
to be high-risk patients, who are often denied for lung trans-
plantation by many centers even if they were without
ECMO preoperatively. These data indicate that our program
has a compassionate, aggressive posture giving critically ill
patients on ECMO a chance of undergoing lung transplan-
tation rather than denying them.
Since the implementation of the LAS system in May
2005 by the Organ Procurement and Transplantation Net-
work, it has dramatically changed lung allocation from
a system based purely on waiting time to an algorithm based
on survival probability on the waiting list and after trans-
plantation. The LAS has significantly reduced the waiting
time and altered the distribution of lung diseases for which
transplantation was performed on the basis of medical
necessity.8 In our study, the mean waiting time was only 7
days (171  242 hours) for patients on pretransplant
ECMO, all of whom had a high LAS (87 vs 44 in the control
group; P ¼ .0001, Table 1).
Although patients can tolerate ECMO with improved
technology,1 the shorter the duration, the better the out-
comes should be for obvious reasons, such as muscular de-
conditioning of the patients, blood loss or hemolysis, blood
transfusions that can sensitize the patients, systemic or pul-
monary thromboembolism, bleeding, infection, stroke, and
so forth. One of the most common reasons why we turn
down lung offers is size discrepancy, particularly for pa-
tients with small chest cavities. To overcome this issue,The Journal of Thoracic and Carwe have performed cadaveric lobar transplantation for 6 pa-
tients on pretransplant ECMO (Table 3). We determined
which lobes were resected at the back table before implan-
tation according to recipients’ chest cavity and the size and
quality of the donor lungs. All patients are surviving at the
follow-up between 220 and 2476 days. Cadaveric lobar
transplantation seems a viable option to shorten the waiting
time and to achieve good outcomes especially for critically
ill patients who cannot wait any longer, although long-term
outcomes need to be determined.
Our patients with pretransplant ECMO had significantly
higher rates of primary graft dysfunction requiring ECMO
support postoperatively (54% vs 6%) and longer median
hospital stay (46 vs 27 days, P ¼ .16). This is in agreement
with the findings previously reported.3,9 The reasons for the
higher rates of primary graft dysfunction need to be
clarified, but because of ECMO circulation and
anticoagulation for the ECMO, patients are in a systemic
inflammatory status and are coagulopathic, requiring
more blood transfusions. We speculate these may be
contributing factors. Patients who received pretransplant
ECMO and required post-transplant ECMO for severe pri-
mary graft dysfunction received significantly greater
amounts of blood transfusion (32  20 units) compared
with patients who received pretransplant ECMO but did
not require post-transplant ECMO (17  9 units). Our
data also suggest that experienced surgeons have less likeli-
hood of requiring post-transplant ECMO (3 of 12; 25%) for
severe primary graft dysfunction compared with less expe-
rienced surgeons (10 of 12; 83%).
Despite higher rates of primary graft dysfunction and lon-
ger hospital stay, hospital mortality and 1- and 2-year sur-
vivals have not been adversely affected. The recipients
with pretransplant ECMO showed similar (P ¼ .787)
survivals comparedwith the no ECMOgroup, with pretrans-
plant ECMO versus no ECMO survival of 96% versus 97%
at 30 days, 83% versus 90% at 6 months, 74% versus 83%
at 1 year, and 74% and 74% at 2 years, respectively
(Figure 1). These survivals were better compared with
UNOS data that included both pre-LAS and post-LAS era:
The 30-day, 6-month, and 1- and 2-year survivals for
patients with pretransplantation ECMO were 72%, 53%,
50%, and 45%, respectively.3 A shorter waiting time for pa-
tients receiving pretransplant ECMO in the LAS era might
contribute to better outcomes. In this study, we performed
double lung transplantation for all of the patients with pre-
transplant ECMO, whereas in the UNOS data, only 57%
of patients received double lung transplantation. Because
the registry data show2 that survival is better with double
lung transplantation versus single lung transplantation, this
may be one of the reasons why our outcomes were better
than those in theUNOSdata. It is also possible that improved
ECMO technology might have contributed to the better
outcomes, both preoperatively and postoperatively.diovascular Surgery c Volume 145, Number 4 1069
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XPatient selection clearly plays a key role in surgical treat-
ments. During the study period from 2005 to 2011, we con-
sidered ECMO for all patients who were active on our
institutional waiting list or who decompensated during the
lung transplant evaluation process. However, the recipient
age for patients with pretransplant ECMO was significantly
lower than in the control group (46  15 years vs 57  14
years), suggesting that there was selection bias where age
cutoff was lower for pretransplant ECMO consideration
than the standard age cutoff for lung transplantation. We
did not routinely consider ECMO use as a bridge to lung
transplant in acute respiratory distress syndromes. Care-
fully selected patients were considered for lung retransplan-
tation after severe allograft dysfunction, either chronic or
acute after the initial lung transplantation. In our center,
patients with other organ failure (eg, kidney and liver)
were denied for redo lung transplantation. Therefore,
when, for example, renal failure after ECMO developed
in patients, they were in general not considered for lung
transplantation.
The type of ECMO support used to bridge patients (VA
or VV) to lung transplantation did not show a significant
difference in overall survival, although the 1-year survival
seemed higher at 77% with VV ECMO versus 65% with
VA ECMO. At the University of Pittsburgh Medical Cen-
ter, patients who were placed on VA ECMO had cardiac
failure in addition to respiratory failure, whereas patients
on VV ECMO had only respiratory failure. Therefore, pa-
tients who required VA ECMO might be sicker than pa-
tients who required VV ECMO. In addition, arterial
cannulation, which is required for VA ECMO, can cause
more complications, such as leg ischemia, arterial embo-
lism (eg, stroke, ischemic gut), and bleeding complication
with more intense anticoagulation. To avoid leg ischemia,
we routinely inserted a distal perfusion cannula when
a femoral artery was used for arterial cannulation. For
VV ECMO, femoral vein to internal jugular vein was the
most common cannulation site in this study. However, we
and others have reported the use of a bicaval dual-lumen
catheter as a bridge to lung transplantation.10-12 The
potential advantage with this cannula is to allow patients
to ambulate while waiting for lung transplantation so that
muscular deconditioning can be avoided. In this study, 3
patients received a single dual-lumen catheter for VV
ECMO; however, they also required mechanical ventilation
for adequate oxygenation. The efficacy of this cannula and
VV versus VA ECMO needs to be clarified through further
experience.
Study Limitations
This single-center study is a small-scale, retrospective
analysis with a short follow-up period. As such, the findings
of this study are limited, and a prospective, multicenter
study would provide more definitive conclusions.1070 The Journal of Thoracic and Cardiovascular SurCONCLUSIONS
After the implementation of the LAS system in 2005,
ECMO as a bridge to lung transplantation is safe and effica-
cious to support patients until donor lungs become available.
ECMO provides excellent survival when it is used in care-
fully selected patients and when lung transplants are per-
formed by experienced surgeons, resulting in less blood loss.
The authors thank Yoshiko Toyoda at Cornell University,
Mohammed A. Kashem, MD, PhD, and T. Sloane Guy, MD, at
Temple University, and Victoria S. Dougherty, BA, for scientific
and administrative assistance.
References
1. MacLaren G, Combes A, Bartlett RH. Contemporary extracorporeal membrane
oxygenation for adult respiratory failure: life support in the new era. Intensive
Care Med. 2012;38:210-20.
2. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dobbels F, Kirk R, et al.
The Registry of the International Society for Heart Lung Transplantation:
Twenty-eighth Adult Lung and Heart-Lung Transplant Report—2011. J Heart
and Lung Transplant. 2011;30:1104-22.
3. Mason D, Thuita L, Nowicki E, Murthy SC, Pettersson GB, Blackstone EH.
Should lung transplantation be performed for patients on mechanical respiratory
support? The US experience. J Thorac Cardiovasc Surg. 2010;139:765-73.
4. Egan TM, Murray S, Bustami RT, Shearon TH, McCullough KP, Edwards LB,
et al. Development of the New Lung Allocation System in the United States.
Am J Transplant. 2006;6:1212-27.
5. Egan TM, Kotloff RM. Pro/con debate: lung allocation should be based onmedical
urgency and transplant survival and not on waiting time. Chest. 2005;128:407-15.
6. Bermudez CA, Rocha RV, Zaldonis D, Bhama JK, Crespo MM, Shigemura N,
et al. Extracorporeal membrane oxygenation as a bridge to lung transplant: mid-
term outcomes. Ann Thorac Surg. 2011;92:1226-32.
7. Toyoda Y, Thacker J, Santos R, Nguyen D, Bhama J, Bermudez C, et al. Long-
term outcome of lung and heart-lung transplantation for idiopathic pulmonary ar-
terial hypertension. Ann Thorac Surg. 2008;86:1116-22.
8. Shyu S, Dew MA, Pilewski JM, DeVito Dabbs AJ, Zaldonis DB, Studer SM,
et al. Five-year outcomes with alemtuzumab induction after lung transplantation.
J Heart Lung Transplant. 2011;30:743-54.
9. Kozower BD, Meyers BF, Smith MA, De Oliveira NC, Cassivi SD, Guthrie TJ,
et al. The impact of the lung allocation score on short-term transplantation out-
comes: a multicenter study. J Thorac Cardiovasc Surg. 2008;135:166-71.
10. Bermudez CA, Rocha RV, Sappington PL, Toyoda Y,Murray HN, Boujoukos AJ.
Initial experiencewith single cannulation for venovenous extracorporeal oxygen-
ation in adults. Ann Thorac Surg. 2010;90:991-5.
11. Fuehner T, Kuehn C, Hadem J, Wiesner O, Gottlieb J, Tudorache I, et al. Extra-
corporeal membrane oxygenation in awake patients as bridge to lung transplan-
tation. Am J Respir Crit Care Med. 2012;185:762-8.
12. Olsson KM, Simon A, Strueber M, Hadem J, Wiesner O, Gottlieb J, et al. Extra-
corporeal membrane oxygenation in nonintubated patients as bridge to lung
transplantation. Am J Transplant. 2010;10:2173-8.Discussion
Dr Charles Hoopes (Lexington, Ky). Yoshi, let me start by
commending you and your former colleagues at the University
of Pittsburgh for your interest in a complex and difficult patient
group. I think you are correct that historically these patients
were not listed for transplant or, if they were listed, frequently
died on the ventilator secondary to a failure of mechanical
ventilation.
However, having said this and sharing with you a common ex-
perience and belief that there is in fact a role for mechanical circu-
latory support technologies in this patient group, it would also be
fair to say that ours is a minority view and it is worth at least notinggery c April 2013
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available in your own database.
As your retrospective study demonstrates, more than half of the
patients undergoing transplantation from an ECMO bridge re-
quired ongoing extracorporeal support for primary graft dysfunc-
tion, and there is generally little debate that early allograft
dysfunction is a predictor of early mortality and late allograft mor-
bidity. It is clearly a predictor of prolonged postoperative courses
as was demonstrated by your institutional study, where the average
was 46 days for the bridging group as opposed to 27 days for those
without a bridge, and it is fair to say that this is associated with
a significant increase in health care costs.
In addition, as you noted, 6 of the 24 patients undergoing trans-
plantation from ECMO received cadaveric lobar transplants
because of donor–recipient size mismatches and the understand-
able need to limit the time of support on ECMO. So for those of
us who may be cynics in the audience, it would be easy to view
ECMO bridging as an expensive technology deployed in high-
risk patients who subsequently receive high-risk allografts,
albeit—and our experience has been the same—with comparable
outcomes at 1 and 2 years.
However, putting the study in that context, let me ask you 1
question with basically 3 simple parts. First, from a philosophical
standpoint, do you think that ECMO should be deployed as salvage
in these patients awaiting transplantation, or should mechanical
circulatory support in lung transplantation follow the same para-
digm we currently follow in cardiac transplantation? In short,
shouldn’t ECMO take an unstable patient and create a lower-risk
patient capable of a lower-risk transplant? In relation to that com-
ment, if we are going to continue using ECMO bridging as salvage
therapy for medically refractory patients failing mechanical venti-
lation, should we not consider once again the use of regionaliza-
tion of donor organs rather than the traditional system of local
centers first so as to prioritize organs to unstable patients on
ECMO? And finally from a purely philosophical standpoint, do
you see ECMO bridging as an evolving standard of care or should
public health policy make this application of technology available
only at a limited number of experienced referral centers?
Again, congratulations on dealing with this complex patient
population, and I look forward to your comments.
Dr Toyoda. Let me comment on the frequency of postoperative
ECMO use. I must admit we had a lower threshold to keep the
ECMO going post-transplant because the patient was already can-
nulated. As you know, some centers use intraoperative ECMO to
perform lung transplants, and they routinely keep the ECMO post-
operatively. In this study, we were able to wean the ECMO early
postoperatively in 4 patients, so ECMO might not be necessary
for these 4 patients. Having said that, we still had approximately
30% to 40% of patients who required ECMO.
In terms of salvage, at the University of Pittsburgh we used
ECMO as salvage in this study. I think that is okay, because our
study shows a 74% 2-year survival rate for the patients who other-
wise would surely die then. We surgeons want to use our abilities
to save patients’ lives, so I think this is okay.
Regarding regionalization, I agree with you. For the sick pa-
tients, I think regionalization would be better than local center first
policy. So we should review our lung allocation strategy.The Journal of Thoracic and CarIn terms of centers, I am not so sure we should limit to certain
centers, because the surgeon’s experience is more important. Even
in this study, an experienced surgeon who had performed more
than 100 lung transplants had a better outcome in postoperative
ECMOuse and bleeding, and shorter warm ischemic time, hospital
stay, and survival. So I don’t think we should limit centers.
Dr Craig Smith (New York, NY). Dr Toyoda, I am looking for
ways to make these data look better. Have you compared the out-
comes in this group on ECMO with the patients in the other group
who required cardiopulmonary bypass for double lungs?
Dr Toyoda.We did not analyze that, but that is a good idea and
we will do it.
Dr R. Duane Davis (Durham, NC). Congratulations on an ex-
cellent series in obviously a difficult cohort of patients. I am going
to follow-up what Dr Hoopes has said. Shouldn’t we start thinking
about this as a way of improving the candidacy of a lung transplant
recipient, instead of just getting them to transplant, make them bet-
ter? You had a 45-day length of stay. One of the things that we have
seen is we got away from doing bedbound support with ECMO and
started focusing on ambulatory ECMO. Then they start actually
behaving like any other lung transplant recipient. The concept
that has actually come out of Germany in terms of going preferen-
tially to ECMO compared with ventilation and all the complica-
tions you buy with that type of strategy certainly seem to make
a better recipient and outcome.
I would also be cautious to say that this should be widespread to
any center. If you look at the UNOS data set and say what are the
outcomes on all-comers for ECMO, they still are not really in an
acceptable range.At single centers that have a focus on this, the out-
comes can be acceptable, but you cannot say that they are the same.
If you are trying to say the 74% in yours is exactly the same as your
all-comers, that is just a statistical fluke of a low number of patients.
Higher risk, you are going to have less good outcomes.
Dr Matthias Loebe (Houston, Tex). I have 2 quick questions.
Can you expand on how many patients were put on ECMO in
your institution who did not reach the point to be transplant candi-
dates and then did not undergo transplantation? In other words,
what is your selection from a patient on ECMO to undergo
transplantation?
Can you comment on the lung allocation strategies? You men-
tioned repeatedly the fact that a LAS at this point does not get
any extra points for being on mechanical support. The opposite is
true that if you are put on mechanical support, pulmonary pressure
goes down, or even if you are extubated, that will give you a certain
disadvantage in organ allocation, as you know. So do you have any
suggestions how to deal with this problem?
Dr Toyoda. During this time period we put an additional 7 pa-
tients on ECMO, but they did not reach lung transplantation. So,
the success bridge rate is approximately 77%. But of those 7 pa-
tients, our decision was wrong in probably 3, because patients
had multiorgan failure at the time of ECMO. So the real success
rate may be 86% or so.
In terms of lung allocation, once a patient is on ECMO, we
should consider that fraction of expired oxygen is 100% for
those patients. ECMO is providing 100% oxygenation. So even
if patients are extubated, we should probably give them a high
score.diovascular Surgery c Volume 145, Number 4 1071
